(July 11, 2024, 10:03 AM EDT) -- WASHINGTON, D.C. — A patent examiner erred in rejecting as obvious a patent application for a fibromyalgia treatment that uses an antihistamine because the examiner failed to show that the referenced prior arts taught that the disease is induced by histamine, a Patent Trial and Appeal Board (PATB) panel found in reversing the examiner’s rejection....